Die beiden Neuinvestoren komplettieren die Seed-Finanzierung. Mit dem nun eingeworbenen Kapital plant Redwave den Abschluss der invasiven Validierungsstudie und den Markteintritt in 2019!
We deliver the first algorithm for everybody to:
Benefit from a faster and more successful hypertension therapy.
Get all the information you were always looking for about your health status.
Monitor your health now and have a safe and healthy life.
(53, General Practitioner)
“I’m really looking forward to get the Redwave product. Finally, I can optimize the treatment of my hypertension patients.”
(37, Construction Engineer)
“Almost all of my family is suffering from high blood pressure. With Redwave I can detect my own risk way earlier.”
“I have high blood pressure for 5 years. Although I take my meds, I’m afraid to get a heart attack. With Redwave I can control my risk.”
Redwave Medical is supported by the Free State of Thuringia with resources of the European Social Fund (ESF).
This project has received funding from the European Unions´s Horizon 2020 research and innovation programme under grant agreement No 815837.